enCore Energy has completed distributing 35 million Verdera Energy shares to its shareholders, granting them direct ownership in Verdera's ISR uranium assets in New Mexico. The shares include unrestricted and restricted classes, with restrictions lifting in November 2026 and February 2027. This move broadens Verdera's shareholder base and aligns with its goal to advance domestic uranium supply amid growing U.S. demand. Verdera aims to build value for shareholders as it develops significant uranium resources in a key U.S. district.
Verdera Energy's share distribution to enCore Energy shareholders provides context for Basic Materials sector trading on Pluang. As of Oct 02, 2026 02:41 WIB, 9 of 38 priced Basic Materials stocks rose while 28 fell. Notable prices include Rio Tinto at USD 92.72 with a 1-day change of -1.54%, Agnico Eagle Mines Ltd at USD 180.62 with 100% buy order activity, and Air Products & Chemicals, Inc. at USD 272.65 with 58% sell order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
